Mutation of SLC 35 D 3 Causes Metabolic Syndrome by Impairing Dopamine Signaling in Striatal

--Manuscript Draft,Wei Li,Zhe Zhang,Chanjuan Hao,Chang-Gui Li,Dong-Jie Zang,J. Zhao,Xiaonan Li,A. Wei,Zong-Bo Wei,Lin Yang,Xin He,Xue-chu Zhen,Xiang Gao,J. Speakman,R. Spritz
2013-01-01
Abstract:43 Obesity is one of the largest health problems facing the world today. Although twin and 44 family studies suggest about two-thirds of obesity is caused by genetic factors, only a small 45 fraction of this variance has been unraveled. There are still large numbers of genes to be 46 identified that cause variations in body fatness and the associated diseases encompassed in 47 the metabolic syndrome (MetS). A locus near a sequence tagged site (STS) marker 48 D6S1009 has been linked to obesity or body mass index (BMI). However, its genetic 49 entity is unknown. D6S1009 is located in the intergenic region between SLC35D3 and 50 NHEG1. Here we report that the ros mutant mice harboring a recessive mutation in the 51 Slc35d3 gene show obesity and MetS and reduced membrane dopamine receptor D1 52 (D1R) with impaired dopamine signaling in striatal neurons. SLC35D3 is localized to 53 both endoplasmic reticulum (ER) and early endosomes and interacts with D1R. In ros 54 striatal D1 neurons, lack of SLC35D3 causes the accumulation of D1R on the ER to impair 55 its ER exit. The MetS phenotype is reversible by the administration of D1R agonist to the ros 56 mutant. In addition, we identified two mutations in the SLC35D3 gene in patients with 57 MetS, which alter the subcellular localization of SLC35D3. Our results suggest that the 58 SLC35D3 gene, close to the D6S1009 locus, is a candidate gene for MetS, which is 59 involved in metabolic control in the central nervous system by regulating dopamine 60 signaling. 61
What problem does this paper attempt to address?